Young-Ho and colleagues found that HP1β (CBX1) depleted BC cells were hypersensitive to PARP inhibitor, compromised HP1βabundance may serve as a useful predictive marker for chemotherapy [38]. This evidence concerns the gene TFF3 and breast cancer.